Chronic pathologies, such as cancer and autoimmunity, are associated with an increase in the number of malignant B cells in circulation. CD20 is a marker for B cells, and its expression increases under conditions of activation, making it a good therapeutic target. The use of anti-CD20 monoclonal antibodies has proven to be useful for the treatment of various pathologies.

At UDIBI we have platforms for the discovery of therapeutic antibodies. The antibodies that we have generated, requested by clients in national and foreign territory, have similar characteristics to the reference antibodies.

Our team of experts is developing therapeutic antibodies, including a specific one against CD20 to produce the Rituximab biosimilar with the aim of offering affordable biological therapy for the Mexican population. Our project is funded by CONACYT, through its research and advocacy projects program (PRONAII). The goal of this project is to generate a human anti-CD20 antibody, with optimized biological and physicochemical characteristics, available for non-clinical and clinical trials in collaboration with Mexican health institutions and companies